Patents Assigned to Thomas Jefferson Univeristy
  • Publication number: 20030064080
    Abstract: The present invention is directed to compositions and methods of treating cancer. The compositions of the present invention include a composition prepared from a tumor cell which is hapten modified and syngeneic to the type of tumor to be treated. The composition has the properties, when administered with an adjuvant to a human suffering from a malignant tumor of the same type as said tumor cell, of eliciting T lymphocytes that infiltrate the tumor of said human, of eliciting an inflammatory immune response against the tumor of said human, and of eliciting a delayed-type hypersensitivity response to the tumor of said human. The methods of the present invention are directed to treating cancer comprising administering a therapeutically effective amount of a composition comprising a tumor cell.
    Type: Application
    Filed: December 19, 2001
    Publication date: April 3, 2003
    Applicant: Thomas Jefferson Univeristy
    Inventor: David Berd
  • Patent number: 6417328
    Abstract: In accordance with the present invention, there are provided isolated mammalian TRAIL receptor proteins, antibodies thereto, therapeutic compositions, and nucleic acids encoding such. Bioassays and therapeutic methods employing invention DR5 and TRAIL-R3 proteins are also provided.
    Type: Grant
    Filed: August 14, 1998
    Date of Patent: July 9, 2002
    Assignee: Thomas Jefferson Univeristy
    Inventor: Emad S. Alnemri